Low-Dose Interleukin-2 Reverses Traumatic Brain Injury-Induced Cognitive Deficit and Pain in a Murine Model.

Katherine CzerpaniakLeandro Flores do NascimentoTingting GuoJintao ZhangXuemei LiuMojdeh SarzaeimZachary D FineYu-Qing Cao

Published in: Annals of neurology (2024)

These results suggest that the beneficial effects of LD-IL-2 treatment are mediated through the expansion of meningeal Treg cells. Collectively, our study identifies Treg as a cellular target and LD-IL-2 as a promising therapy for both chronic PTH and mTBI-induced cognitive impairment for both males and females, with a wide therapeutic time window and the potential of reducing polypharmacy in mTBI treatment. ANN NEUROL 2024;96:508-525.

Keyphrases

traumatic brain injury
low dose
cognitive impairment
diabetic rats
chronic pain
induced apoptosis
drug induced
oxidative stress
emergency department
pain management
gene expression
mild traumatic brain injury
spinal cord injury
smoking cessation
replacement therapy
endoplasmic reticulum stress